Meanwhile, it is well understood that accelerated cancer progression can be attributed to excessive activation of PI3K subunit, including PIK3CA, and many PI3K inhibitors are used for cancer therapies in clinical trials (37). The gene discussed is PIK3CA; the disease is cancer.